KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Debt Issuances (2020 - 2024)

Historic Long-Term Debt Issuances for AbCellera Biologics (ABCL) over the last 3 years, with Q3 2024 value amounting to $3.1 million.

  • AbCellera Biologics' Long-Term Debt Issuances fell 5271.34% to $3.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $14.2 million, marking a year-over-year increase of 11583.84%. This contributed to the annual value of $872000.0 for FY2021, which is 9437.06% down from last year.
  • Latest data reveals that AbCellera Biologics reported Long-Term Debt Issuances of $3.1 million as of Q3 2024, which was down 5271.34% from $2.4 million recorded in Q2 2024.
  • In the past 5 years, AbCellera Biologics' Long-Term Debt Issuances registered a high of $16.2 million during Q1 2020, and its lowest value of -$662000.0 during Q2 2020.
  • Over the past 3 years, AbCellera Biologics' median Long-Term Debt Issuances value was $2.2 million (recorded in 2024), while the average stood at $3.7 million.
  • Examining YoY changes over the last 5 years, AbCellera Biologics' Long-Term Debt Issuances showed a top increase of 5271.34% in 2024 and a maximum decrease of 5271.34% in 2024.
  • AbCellera Biologics' Long-Term Debt Issuances (Quarter) stood at -$26000.0 in 2020, then skyrocketed by 25330.77% to $6.6 million in 2023, then crashed by 52.71% to $3.1 million in 2024.
  • Its Long-Term Debt Issuances stands at $3.1 million for Q3 2024, versus $2.4 million for Q2 2024 and $2.1 million for Q1 2024.